Drug profile · INN
quizartinib dihydrochloride
VANFLYTA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
quizartinib dihydrochloride (VANFLYTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN quizartinib dihydrochloride
Brand VANFLYTA
Route ORAL
Formulation TABLET
Frequently asked questions
What is quizartinib dihydrochloride?
quizartinib dihydrochloride (VANFLYTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for quizartinib dihydrochloride?
VANFLYTA is a marketed brand name for quizartinib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of quizartinib dihydrochloride?
quizartinib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.